These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 8339257)
1. Potentiation of a three drug chemotherapy regimen by radiation. Koutcher JA; Alfieri AA; Stolfi RL; Devitt ML; Colofiore JR; Nord LD; Martin DS Cancer Res; 1993 Aug; 53(15):3518-23. PubMed ID: 8339257 [TBL] [Abstract][Full Text] [Related]
2. Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion. Nord LD; Stolfi RL; Alfieri AA; Netto G; Reuter V; Sternberg SS; Colofiore JR; Koutcher JA; Martin DS Cancer Chemother Pharmacol; 1997; 40(5):376-84. PubMed ID: 9272113 [TBL] [Abstract][Full Text] [Related]
3. Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination. Stolfi RL; Colofiore JR; Nord LD; Koutcher JA; Martin DS Cancer Res; 1992 Aug; 52(15):4074-81. PubMed ID: 1379119 [TBL] [Abstract][Full Text] [Related]
4. Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression. Colofiore JR; Stolfi RL; Nord LD; Martin DS Biochem Pharmacol; 1995 Nov; 50(11):1943-8. PubMed ID: 8615876 [TBL] [Abstract][Full Text] [Related]
5. Cancer chemotherapy: past is prologue. Martin DS Mt Sinai J Med; 1985 Jun; 52(6):426-34. PubMed ID: 3875021 [No Abstract] [Full Text] [Related]
6. In vivo detection by 31P NMR of pentose phosphate pathway block secondary to biochemical modulation. Mahmood U; Street JC; Matei C; Ballon D; Martin DS; Koutcher JA NMR Biomed; 1996 May; 9(3):114-20. PubMed ID: 8892397 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of chemotherapy and radiation enhancement and 31P NMR spectral changes induced by biochemical modulation. Koutcher JA; Alfieri AA; Tsai JC; Matei C; Stolfi RL; Ballon D; Martin DS Cancer Invest; 1997; 15(2):111-20. PubMed ID: 9095206 [TBL] [Abstract][Full Text] [Related]
8. Correlation of retention of tumor methylmercaptopurine riboside-5'-phosphate with effectiveness in CD8F1 murine mammary tumor regression. Nord LD; Stolfi RL; Colofiore JR; Martin DS Biochem Pharmacol; 1996 Mar; 51(5):621-7. PubMed ID: 8615898 [TBL] [Abstract][Full Text] [Related]
9. Radiation enhancement by biochemical modulation and 5-fluorouracil. Koutcher JA; Alfieri AA; Thaler H; Matei C; Martin DS Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1145-52. PubMed ID: 9392557 [TBL] [Abstract][Full Text] [Related]
10. Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation. Martin DS; Stolfi RL; Colofiore JR; Nord LD Anticancer Drugs; 1996 Aug; 7(6):655-9. PubMed ID: 8913434 [TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation. Stolfi RL; Colofiore JR; Nord LD; Martin DS Anticancer Drugs; 1996 Jan; 7(1):100-4. PubMed ID: 8742105 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Martin DS; Schwartz GK Oncol Res; 1997; 9(1):1-5. PubMed ID: 9112254 [TBL] [Abstract][Full Text] [Related]
13. Biochemical modulation of tumor cell energy in vivo: II. A lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed. Martin DS; Stolfi RL; Colofiore JR; Nord LD; Sternberg S Cancer Invest; 1994; 12(3):296-307. PubMed ID: 8187007 [TBL] [Abstract][Full Text] [Related]
14. Biochemical modulation: application of laboratory models to the clinic. Leyland-Jones B; O'Dwyer PJ Cancer Treat Rep; 1986 Jan; 70(1):219-29. PubMed ID: 3510736 [No Abstract] [Full Text] [Related]
15. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma. Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669 [TBL] [Abstract][Full Text] [Related]
16. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cao S; Rustum YM; Spector T Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256 [TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity of fluorouracil with N-phosphonacetyl-L-aspartate. Stenram U Ann Intern Med; 1992 Jul; 117(1):90-1. PubMed ID: 1530700 [No Abstract] [Full Text] [Related]
18. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer. Kemeny N; Schneider A; Martin DS; Colofiore J; Sawyer RC; Derby S; Salvia B Cancer Res; 1989 Aug; 49(16):4636-9. PubMed ID: 2472883 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma. Kensler TW; Reck LJ; Cooney DA Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876 [No Abstract] [Full Text] [Related]
20. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Casper ES; Young CW Cancer Res; 1983 May; 43(5):2317-21. PubMed ID: 6187448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]